{
  "medications": [
    {
      "name": "Metformin",
      "generic_name": "metformin hydrochloride",
      "brand_names": ["Glucophage", "Fortamet", "Riomet", "Glumetza", "Obimet", "Dianben", "Diaformin", "Siofor"],
      "drug_class": "biguanide",
      "indication": "Type 2 diabetes mellitus, Polycystic ovary syndrome (off-label)",
      "mechanism": "Decreases hepatic glucose production, decreases intestinal glucose absorption, improves insulin sensitivity by increasing peripheral glucose uptake and utilization",
      "dosage_forms": ["tablet", "extended-release tablet", "oral solution", "suspension"],
      "common_dosages": ["500mg", "850mg", "1000mg", "500mg ER", "750mg ER", "1000mg ER"],
      "side_effects": ["nausea", "diarrhea", "abdominal discomfort", "flatulence", "lactic acidosis", "vitamin B12 deficiency", "metallic taste", "anorexia"],
      "contraindications": ["severe kidney disease (eGFR <30 mL/min)", "metabolic acidosis", "diabetic ketoacidosis", "severe liver disease", "alcohol abuse", "conditions predisposing to renal failure"],
      "black_box_warnings": ["Lactic acidosis risk"],
      "pregnancy_category": "B",
      "half_life": "6.2 hours",
      "metabolism": "Not metabolized",
      "excretion": "Renal (90% unchanged)",
      "monitoring_parameters": ["Renal function", "HbA1c", "Vitamin B12 levels", "LFTs"],
      "drug_interactions": ["Iodinated contrast media", "Alcohol", "Cimetidine", "Topiramate", "Carbonic anhydrase inhibitors"],
      "patient_instructions": ["Take with meals to reduce GI upset", "Do not crush or chew extended-release tablets", "Avoid excessive alcohol consumption", "Report symptoms of lactic acidosis (muscle pain, breathing difficulty, stomach discomfort)"]
    },
    {
      "name": "Lisinopril",
      "generic_name": "lisinopril",
      "brand_names": ["Prinivil", "Zestril", "Acemin", "Alapril", "Dapril", "Liprace", "Listril", "Prinil"],
      "drug_class": "Angiotensin-converting enzyme (ACE) inhibitor",
      "indication": "Hypertension, heart failure, post-myocardial infarction, diabetic nephropathy",
      "mechanism": "Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Reduces aldosterone secretion, decreasing sodium and water retention.",
      "dosage_forms": ["tablet", "oral solution"],
      "common_dosages": ["2.5mg", "5mg", "10mg", "20mg", "30mg", "40mg"],
      "side_effects": ["dry cough", "hyperkalemia", "angioedema", "hypotension", "dizziness", "headache", "renal impairment", "rash", "taste disturbance"],
      "contraindications": ["pregnancy", "history of angioedema", "bilateral renal artery stenosis", "concomitant use with aliskiren in patients with diabetes"],
      "black_box_warnings": ["Fetal toxicity"],
      "pregnancy_category": "D",
      "half_life": "12 hours",
      "metabolism": "Not metabolized",
      "excretion": "Renal (unchanged)",
      "monitoring_parameters": ["Blood pressure", "Renal function", "Serum potassium", "Angioedema symptoms"],
      "drug_interactions": ["Diuretics", "NSAIDs", "Potassium-sparing diuretics", "Potassium supplements", "Lithium", "Aliskiren"],
      "patient_instructions": ["Take at same time each day", "Report swelling of face/lips/tongue, difficulty breathing", "Rise slowly from sitting/lying position", "Monitor for persistent dry cough", "Avoid potassium supplements unless prescribed"]
    },
    {
      "name": "Atorvastatin",
      "generic_name": "atorvastatin calcium",
      "brand_names": ["Lipitor", "Atorva", "Torvast", "Totalip", "Liptor", "Atocor", "Storvas"],
      "drug_class": "HMG-CoA reductase inhibitor (statin)",
      "indication": "Hyperlipidemia, primary prevention of cardiovascular disease, secondary prevention of cardiovascular events, heterozygous familial hypercholesterolemia",
      "mechanism": "Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Increases hepatic LDL receptors, enhancing clearance of LDL from bloodstream.",
      "dosage_forms": ["tablet", "oral suspension"],
      "common_dosages": ["10mg", "20mg", "40mg", "80mg"],
      "side_effects": ["myalgia", "arthralgia", "headache", "nausea", "constipation", "diarrhea", "liver enzyme elevation", "rhabdomyolysis", "increased blood glucose"],
      "contraindications": ["active liver disease", "pregnancy", "breastfeeding", "unexplained persistent elevations of serum transaminases"],
      "black_box_warnings": ["Rhabdomyolysis risk", "Liver enzyme abnormalities"],
      "pregnancy_category": "X",
      "half_life": "14 hours",
      "metabolism": "Hepatic (CYP3A4)",
      "excretion": "Primarily biliary",
      "monitoring_parameters": ["Lipid panel", "LFTs", "CPK if symptomatic", "HbA1c in diabetics"],
      "drug_interactions": ["Cyclosporine", "Gemfibrozil", "Macrolide antibiotics", "Azole antifungals", "Protease inhibitors", "Grapefruit juice", "Niacin", "Colchicine"],
      "patient_instructions": ["Take at any time of day (with or without food)", "Report unexplained muscle pain/tenderness/weakness", "Avoid excessive grapefruit juice consumption", "Follow cholesterol-lowering diet", "Regular exercise program"]
    },
    {
      "name": "Omeprazole",
      "generic_name": "omeprazole",
      "brand_names": ["Prilosec", "Losec", "Omesec", "Omepral", "Gasec", "Mopral", "Zegerid", "Lomac"],
      "drug_class": "Proton pump inhibitor",
      "indication": "GERD, erosive esophagitis, peptic ulcer disease, H. pylori eradication (in combination), Zollinger-Ellison syndrome, NSAID-induced ulcer prophylaxis",
      "mechanism": "Irreversibly blocks the H+/K+-ATPase enzyme system (proton pump) in gastric parietal cells, inhibiting the final step of acid production.",
      "dosage_forms": ["delayed-release capsule", "tablet", "oral suspension", "powder for suspension", "injection"],
      "common_dosages": ["10mg", "20mg", "40mg", "20mg/1680mg sodium bicarbonate (Zegerid)"],
      "side_effects": ["headache", "abdominal pain", "nausea", "diarrhea", "constipation", "flatulence", "C. difficile infection", "bone fractures", "hypomagnesemia", "vitamin B12 deficiency", "acute interstitial nephritis"],
      "contraindications": ["hypersensitivity to benzimidazoles", "concomitant use with rilpivirine"],
      "black_box_warnings": ["None"],
      "pregnancy_category": "C",
      "half_life": "0.5-1 hour (prolonged with repeated dosing due to covalent binding)",
      "metabolism": "Hepatic (CYP2C19, CYP3A4)",
      "excretion": "Renal (77%)",
      "monitoring_parameters": ["Symptoms of GERD/PUD", "Magnesium levels with prolonged use", "Bone density with long-term use", "Renal function"],
      "drug_interactions": ["Clopidogrel", "Warfarin", "Diazepam", "Phenytoin", "Digoxin", "Methotrexate", "Cilostazol", "Tacrolimus", "HIV protease inhibitors"],
      "patient_instructions": ["Take before meals (typically 30-60 minutes before breakfast)", "Do not crush or chew delayed-release formulations", "Report persistent diarrhea, bone pain, muscle spasms", "Consider calcium and vitamin D supplementation with long-term use"]
    },
    {
      "name": "Levothyroxine",
      "generic_name": "levothyroxine sodium",
      "brand_names": ["Synthroid", "Levoxyl", "Unithroid", "Eltroxin", "Euthyrox", "Thyrax", "Thyronorm", "Levoid"],
      "drug_class": "Thyroid hormone",
      "indication": "Hypothyroidism, thyroid suppression therapy, myxedema coma, congenital hypothyroidism",
      "mechanism": "Replaces or supplements endogenous thyroid hormone (T4), which is converted to active T3 in peripheral tissues. Regulates growth, development, and metabolic rate.",
      "dosage_forms": ["tablet", "capsule", "injection", "oral solution"],
      "common_dosages": ["25mcg", "50mcg", "75mcg", "88mcg", "100mcg", "112mcg", "125mcg", "137mcg", "150mcg", "175mcg", "200mcg", "300mcg"],
      "side_effects": ["palpitations", "tachycardia", "tremor", "insomnia", "headache", "nervousness", "irritability", "heat intolerance", "sweating", "weight loss", "increased appetite", "arrhythmias", "osteoporosis (overtreatment)"],
      "contraindications": ["untreated adrenal insufficiency", "untreated thyrotoxicosis", "acute myocardial infarction", "uncorrected adrenal insufficiency"],
      "black_box_warnings": ["None for hypothyroidism"],
      "pregnancy_category": "A",
      "half_life": "6-7 days (euthyroid), 9-10 days (hypothyroid)",
      "metabolism": "Hepatic, peripheral deiodination",
      "excretion": "Renal, fecal",
      "monitoring_parameters": ["TSH (primary)", "Free T4", "Clinical symptoms", "Cardiac status in elderly", "Bone density with long-term therapy"],
      "drug_interactions": ["Calcium carbonate", "Iron supplements", "Proton pump inhibitors", "Sucralfate", "Cholestyramine", "Estrogens", "Rifampin", "Phenytoin", "Carbamazepine", "Warfarin"],
      "patient_instructions": ["Take on empty stomach 30-60 minutes before breakfast", "Consistent timing daily", "Separate from other medications by at least 4 hours", "Do not switch brands without medical supervision", "Report symptoms of hyperthyroidism (palpitations, weight loss, nervousness)"]
    },
    {
      "name": "Amlodipine",
      "generic_name": "amlodipine besylate",
      "brand_names": ["Norvasc", "Amdepin", "Amcard", "Amlopin", "Amlovas", "Stamlo", "Amvaz"],
      "drug_class": "Dihydropyridine calcium channel blocker",
      "indication": "Hypertension, chronic stable angina, vasospastic angina",
      "mechanism": "Inhibits calcium ion influx across cell membranes in vascular smooth muscle and cardiac muscle, producing peripheral arterial vasodilation and reducing peripheral vascular resistance.",
      "dosage_forms": ["tablet", "oral suspension"],
      "common_dosages": ["2.5mg", "5mg", "10mg"],
      "side_effects": ["peripheral edema", "headache", "dizziness", "flushing", "palpitations", "fatigue", "nausea", "abdominal pain"],
      "contraindications": ["hypersensitivity to dihydropyridines", "severe hypotension", "aortic stenosis"],
      "black_box_warnings": ["None"],
      "pregnancy_category": "C",
      "half_life": "30-50 hours",
      "metabolism": "Hepatic (extensive)",
      "excretion": "Urine (60%), feces (20-25%)",
      "monitoring_parameters": ["Blood pressure", "Heart rate", "Peripheral edema", "Angina symptoms"],
      "drug_interactions": ["CYP3A4 inhibitors (may increase levels)", "Simvastatin (dose limitation)", "Sildenafil (additive hypotension)"],
      "patient_instructions": ["Take at same time each day", "Rise slowly from sitting/lying position", "Report significant swelling of ankles/feet, dizziness, palpitations", "Do not stop abruptly"]
    },
    {
      "name": "Sertraline",
      "generic_name": "sertraline hydrochloride",
      "brand_names": ["Zoloft", "Lustral", "Apo-Sertral", "Asentra", "Gladem", "Serlift", "Xydep"],
      "drug_class": "Selective serotonin reuptake inhibitor (SSRI)",
      "indication": "Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, premenstrual dysphoric disorder",
      "mechanism": "Selectively inhibits serotonin reuptake in the presynaptic neuron, increasing synaptic serotonin concentration and enhancing serotonergic neurotransmission.",
      "dosage_forms": ["tablet", "oral concentrate"],
      "common_dosages": ["25mg", "50mg", "100mg"],
      "side_effects": ["nausea", "diarrhea", "insomnia", "somnolence", "dry mouth", "headache", "sexual dysfunction", "increased sweating", "tremor", "appetite changes"],
      "contraindications": ["concomitant use with MAOIs or pimozide", "disulfiram (for oral concentrate)"],
      "black_box_warnings": ["Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults"],
      "pregnancy_category": "C",
      "half_life": "26 hours",
      "metabolism": "Hepatic (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4)",
      "excretion": "Urine (40-45%), feces (40-45%)",
      "monitoring_parameters": ["Mental status for depression, anxiety, suicidal ideation", "Mood changes", "Emerging side effects"],
      "drug_interactions": ["MAOIs", "Warfarin", "Tricyclic antidepressants", "Triptans", "NSAIDs", "Antiarrhythmics", "Antipsychotics", "Linezolid", "Methylene blue"],
      "patient_instructions": ["Take with or without food", "Better tolerated with morning administration", "Do not stop abruptly", "Report worsening depression, suicidal thoughts, unusual behavior changes", "May take several weeks to achieve full therapeutic effect"]
    },
    {
      "name": "Albuterol",
      "generic_name": "albuterol sulfate",
      "brand_names": ["ProAir HFA", "Ventolin HFA", "Proventil HFA", "AccuNeb", "VoSpire ER"],
      "drug_class": "Short-acting beta-2 adrenergic agonist",
      "indication": "Bronchospasm in reversible obstructive airway disease, prevention of exercise-induced bronchospasm",
      "mechanism": "Relaxes bronchial smooth muscle by action on beta-2 receptors with minimal effect on cardiac muscle contractility. Stimulates intracellular adenyl cyclase, converting ATP to cAMP, which mediates smooth muscle relaxation.",
      "dosage_forms": ["metered-dose inhaler", "nebulizer solution", "dry powder inhaler", "tablet", "syrup", "extended-release tablet"],
      "common_dosages": ["90mcg/puff (HFA inhalers)", "0.63mg/3mL", "1.25mg/3mL", "2.5mg/3mL (nebulizer)", "2mg", "4mg (tablets)"],
      "side_effects": ["tachycardia", "palpitations", "tremor", "nervousness", "headache", "dizziness", "throat irritation", "hypokalemia", "paradoxical bronchospasm"],
      "contraindications": ["hypersensitivity to sympathomimetic amines", "tachyarrhythmias"],
      "black_box_warnings": ["Asthma-related death (with excessive use)"],
      "pregnancy_category": "C",
      "half_life": "3.8-6 hours",
      "metabolism": "Hepatic",
      "excretion": "Urine (76% within 72 hours, mostly as metabolites)",
      "monitoring_parameters": ["Pulmonary function", "Heart rate", "Blood pressure", "Serum potassium with frequent use", "Symptoms of paradoxical bronchospasm"],
      "drug_interactions": ["Beta-blockers", "Diuretics", "MAOIs", "Tricyclic antidepressants", "Other sympathomimetics"],
      "patient_instructions": ["For inhalation use only", "Shake well before use", "Prime inhaler before first use or if not used for 2 weeks", "Rinse mouth after use to prevent thrush", "Do not exceed recommended dosage", "Seek medical attention if symptoms worsen or not responsive to usual dose"]
    },
    {
      "name": "Warfarin",
      "generic_name": "warfarin sodium",
      "brand_names": ["Coumadin", "Jantoven", "Marevan", "Warfarex", "Waran"],
      "drug_class": "Vitamin K antagonist (oral anticoagulant)",
      "indication": "Prophylaxis and treatment of venous thrombosis, pulmonary embolism, thromboembolic complications associated with atrial fibrillation, cardiac valve replacement, reduced risk of death/recurrent MI after myocardial infarction",
      "mechanism": "Inhibits vitamin K-dependent synthesis of biologically active forms of clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.",
      "dosage_forms": ["tablet"],
      "common_dosages": ["1mg", "2mg", "2.5mg", "3mg", "4mg", "5mg", "6mg", "7.5mg", "10mg"],
      "side_effects": ["bleeding", "skin necrosis", "purple toe syndrome", "alopecia", "rash", "hepatitis", "nausea", "diarrhea"],
      "contraindications": ["hemorrhagic tendencies", "recent surgery", "peptic ulcer disease", "threatened abortion", "uncontrolled hypertension", "spinal puncture", "pericarditis", "subacute bacterial endocarditis"],
      "black_box_warnings": ["Bleeding risk", "Requires regular monitoring"],
      "pregnancy_category": "X",
      "half_life": "20-60 hours (mean 40 hours)",
      "metabolism": "Hepatic (CYP2C9, CYP1A2, CYP3A4)",
      "excretion": "Urine (92%)",
      "monitoring_parameters": ["INR (target range varies by indication)", "Signs/symptoms of bleeding", "CBC", "Stool occult blood"],
      "drug_interactions": ["Many medications including antibiotics, antifungals, antiplatelets, NSAIDs, SSRIs", "Vitamin K-containing foods", "Alcohol", "Herbal supplements (garlic, ginkgo, ginseng, St. John's wort)"],
      "patient_instructions": ["Take at same time each day", "Do not change brands without consulting physician", "Maintain consistent vitamin K intake", "Regular INR monitoring required", "Report signs of bleeding (unusual bruising, blood in urine/stool, headache, dizziness)", "Carry/wear medical identification", "Avoid activities with high risk of trauma"]
    },
    {
      "name": "Insulin Glargine",
      "generic_name": "insulin glargine",
      "brand_names": ["Lantus", "Basaglar", "Toujeo", "Semglee"],
      "drug_class": "Long-acting insulin analog",
      "indication": "Type 1 diabetes mellitus, Type 2 diabetes mellitus",
      "mechanism": "Recombinant human insulin analog with prolonged duration of action. Binds to insulin receptors, facilitating cellular glucose uptake, and regulating protein, carbohydrate, and lipid metabolism.",
      "dosage_forms": ["injection solution", "prefilled pen"],
      "common_dosages": ["100 units/mL", "300 units/mL (Toujeo)"],
      "side_effects": ["hypoglycemia", "hypokalemia", "lipodystrophy", "pruritus", "rash", "allergic reactions", "weight gain", "edema"],
      "contraindications": ["hypoglycemia", "hypersensitivity to insulin glargine or excipients"],
      "black_box_warnings": ["None specific to glargine"],
      "pregnancy_category": "C",
      "half_life": "12-24 hours (dose-dependent)",
      "metabolism": "Liver, kidney, muscle (degraded to smaller peptides and amino acids)",
      "excretion": "Urine",
      "monitoring_parameters": ["Blood glucose", "HbA1c", "Hypoglycemia symptoms", "Potassium levels", "Weight"],
      "drug_interactions": ["Many medications may affect glucose control including corticosteroids, thiazides, beta-blockers, MAOIs", "Alcohol", "Other antidiabetic agents"],
      "patient_instructions": ["Administer subcutaneously once daily at same time", "Do not mix with other insulins", "Rotate injection sites", "Proper storage (refrigerate unopened, room temperature for opened vials/pens)", "Recognize and treat hypoglycemia", "Never share pens or needles"]
    },
    {
      "name": "Gabapentin",
      "generic_name": "gabapentin",
      "brand_names": ["Neurontin", "Gralise", "Horizant", "Gabarone", "Fanatrex"],
      "drug_class": "Gamma-aminobutyric acid (GABA) analog",
      "indication": "Postherpetic neuralgia, partial onset seizures, neuropathic pain, restless legs syndrome (off-label), fibromyalgia (off-label)",
      "mechanism": "Binds to alpha-2-delta subunit of voltage-gated calcium channels, reducing calcium influx and subsequent release of excitatory neurotransmitters. Structural analog of GABA but does not act directly on GABA receptors.",
      "dosage_forms": ["capsule", "tablet", "oral solution", "extended-release tablet"],
      "common_dosages": ["100mg", "300mg", "400mg", "600mg", "800mg", "1200mg ER", "1800mg ER"],
      "side_effects": ["dizziness", "somnolence", "ataxia", "fatigue", "nystagmus", "peripheral edema", "weight gain", "blurred vision", "tremor"],
      "contraindications": ["hypersensitivity to gabapentin"],
      "black_box_warnings": ["None"],
      "pregnancy_category": "C",
      "half_life": "5-7 hours",
      "metabolism": "Not metabolized",
      "excretion": "Renal (unchanged)",
      "monitoring_parameters": ["Renal function", "Seizure frequency", "Pain control", "Mood changes", "Suicidal thoughts/behavior"],
      "drug_interactions": ["Antacids (reduce absorption)", "Opioids (increased CNS depression)", "Alcohol (increased CNS depression)", "Hydrocodone (increased hydrocodone exposure)"],
      "patient_instructions": ["Take with or without food", "Do not abruptly discontinue (taper over at least 1 week)", "Report mood changes, suicidal thoughts", "Avoid alcohol and other CNS depressants", "May cause dizziness/drowsiness - use caution when driving"]
    },
    {
      "name": "Hydrochlorothiazide",
      "generic_name": "hydrochlorothiazide",
      "brand_names": ["Microzide", "Oretic", "Esidrix", "HydroDIURIL", "Aquazide H"],
      "drug_class": "Thiazide diuretic",
      "indication": "Hypertension, edema associated with heart failure, hepatic cirrhosis, renal dysfunction",
      "mechanism": "Inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium, water, chloride, and potassium. Produces vasodilation by unclear mechanisms.",
      "dosage_forms": ["tablet", "capsule"],
      "common_dosages": ["12.5mg", "25mg", "50mg"],
      "side_effects": ["hypokalemia", "hyponatremia", "hypochloremia", "hypomagnesemia", "hypercalcemia", "hyperglycemia", "hyperuricemia", "photosensitivity", "orthostatic hypotension"],
      "contraindications": ["anuria", "hypersensitivity to sulfonamide-derived drugs", "refractory hypokalemia", "severe hepatic impairment"],
      "black_box_warnings": ["None"],
      "pregnancy_category": "B",
      "half_life": "6-15 hours",
      "metabolism": "Not metabolized",
      "excretion": "Renal (unchanged)",
      "monitoring_parameters": ["Blood pressure", "Electrolytes (especially potassium)", "Renal function", "Uric acid", "Glucose"],
      "drug_interactions": ["Lithium", "Digoxin", "Other antihypertensives", "Corticosteroids", "Amphotericin B", "NSAIDs", "Cholestyramine", "Colestipol"],
      "patient_instructions": ["Take in morning to avoid nocturia", "Take with food to reduce GI upset", "Report signs of electrolyte imbalance (muscle cramps, weakness, dizziness)", "Eat potassium-rich foods", "Avoid excessive sun exposure", "Rise slowly from sitting/lying position"]
    },
    {
      "name": "Escitalopram",
      "generic_name": "escitalopram oxalate",
      "brand_names": ["Lexapro", "Cipralex", "Esipram", "Seralite", "Elopram"],
      "drug_class": "Selective serotonin reuptake inhibitor (SSRI)",
      "indication": "Major depressive disorder, generalized anxiety disorder",
      "mechanism": "Potent and highly selective inhibitor of serotonin reuptake. The S-enantiomer of citalopram with twice the potency of racemic citalopram.",
      "dosage_forms": ["tablet", "oral solution"],
      "common_dosages": ["5mg", "10mg", "20mg"],
      "side_effects": ["nausea", "insomnia", "somnolence", "increased sweating", "fatigue", "dry mouth", "dizziness", "diarrhea", "sexual dysfunction", "anxiety"],
      "contraindications": ["concomitant use with MAOIs or pimozide", "QT prolongation", "hypersensitivity to escitalopram or citalopram"],
      "black_box_warnings": ["Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults"],
      "pregnancy_category": "C",
      "half_life": "27-32 hours",
      "metabolism": "Hepatic (CYP2C19, CYP3A4, CYP2D6)",
      "excretion": "Urine (8% unchanged), feces (10%)",
      "monitoring_parameters": ["Mental status for depression, anxiety, suicidal ideation", "ECG in patients with cardiac risk factors", "Emerging side effects"],
      "drug_interactions": ["MAOIs", "Serotonergic drugs", "Drugs that prolong QT interval", "Cimetidine", "Warfarin", "Triptans", "Linezolid", "Methylene blue"],
      "patient_instructions": ["Take with or without food", "Better tolerated with morning administration", "Do not stop abruptly", "Report worsening depression, suicidal thoughts, unusual behavior changes", "May take several weeks to achieve full therapeutic effect"]
    },
    {
      "name": "Losartan",
      "generic_name": "losartan potassium",
      "brand_names": ["Cozaar", "Losacor", "Repace", "Lortaan", "Losarstan"],
      "drug_class": "Angiotensin II receptor blocker (ARB)",
      "indication": "Hypertension, diabetic nephropathy, stroke risk reduction in hypertension with LVH, heart failure (when ACE inhibitor intolerant)",
      "mechanism": "Selectively blocks the binding of angiotensin II to AT1 receptors, preventing angiotensin II-induced vasoconstriction, aldosterone secretion, and sympathetic nervous system activation.",
      "dosage_forms": ["tablet"],
      "common_dosages": ["25mg", "50mg", "100mg"],
      "side_effects": ["dizziness", "hypotension", "hyperkalemia", "hypoglycemia (in diabetics)", "back pain", "leg pain", "upper respiratory infection", "fatigue"],
      "contraindications": ["pregnancy", "hypersensitivity to losartan"],
      "black_box_warnings": ["Fetal toxicity"],
      "pregnancy_category": "D",
      "half_life": "2 hours (parent), 6-9 hours (active metabolite)",
      "metabolism": "Hepatic (CYP2C9, CYP3A4) to active metabolite",
      "excretion": "Urine (35%), feces (60%)",
      "monitoring_parameters": ["Blood pressure", "Renal function", "Serum potassium", "Symptoms of hypotension"],
      "drug_interactions": ["Potassium-sparing diuretics", "Potassium supplements", "NSAIDs", "Lithium", "Fluconazole", "Rifampin"],
      "patient_instructions": ["Take at same time each day", "Report swelling of face/lips/tongue, difficulty breathing", "Rise slowly from sitting/lying position", "Avoid potassium supplements unless prescribed"]
    },
    {
      "name": "Metoprolol",
      "generic_name": "metoprolol tartrate/succinate",
      "brand_names": ["Lopressor", "Toprol XL", "Betaloc", "Kapspargo", "Metoprolol ER"],
      "drug_class": "Selective beta-1 adrenergic blocker",
      "indication": "Hypertension, angina pectoris, heart failure, myocardial infarction, atrial fibrillation/flutter, migraine prophylaxis",
      "mechanism": "Selectively blocks beta-1 adrenergic receptors, reducing heart rate, myocardial contractility, blood pressure, and myocardial oxygen demand.",
      "dosage_forms": ["tablet", "extended-release tablet", "injection"],
      "common_dosages": ["25mg", "50mg", "100mg", "12.5mg", "25mg ER", "50mg ER", "100mg ER", "200mg ER"],
      "side_effects": ["bradycardia", "hypotension", "fatigue", "dizziness", "depression", "shortness of breath", "wheezing", "cold extremities", "sleep disturbances"],
      "contraindications": ["severe bradycardia", "heart block greater than first degree", "cardiogenic shock", "decompensated heart failure", "sick sinus syndrome", "severe peripheral arterial disease"],
      "black_box_warnings": ["Do not abruptly withdraw (may exacerbate angina, MI)"],
      "pregnancy_category": "C",
      "half_life": "3-7 hours (tartrate), longer (succinate ER)",
      "metabolism": "Hepatic (CYP2D6)",
      "excretion": "Urine (95%)",
      "monitoring_parameters": ["Blood pressure", "Heart rate", "ECG", "Symptoms of heart failure", "Blood glucose in diabetics"],
      "drug_interactions": ["Other beta-blockers", "Calcium channel blockers", "Digoxin", "CYP2D6 inhibitors", "Insulin/oral hypoglycemics", "Clonidine", "Antiarrhythmics"],
      "patient_instructions": ["Take with or immediately after meals", "Do not crush or chew extended-release tablets", "Do not stop abruptly", "Monitor pulse rate", "Report shortness of breath, weight gain, edema", "Use caution when driving or operating machinery"]
    },
    {
      "name": "Duloxetine",
      "generic_name": "duloxetine hydrochloride",
      "brand_names": ["Cymbalta", "Drizalma", "Irenka", "Yentreve"],
      "drug_class": "Serotonin-norepinephrine reuptake inhibitor (SNRI)",
      "indication": "Major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, chronic musculoskeletal pain",
      "mechanism": "Potent inhibitor of serotonin and norepinephrine reuptake, and a weaker inhibitor of dopamine reuptake. Enhances serotonergic and noradrenergic activity in the CNS.",
      "dosage_forms": ["delayed-release capsule", "delayed-release tablet"],
      "common_dosages": ["20mg", "30mg", "40mg", "60mg"],
      "side_effects": ["nausea", "dry mouth", "constipation", "decreased appetite", "fatigue", "somnolence", "increased sweating", "dizziness", "insomnia"],
      "contraindications": ["concomitant use with MAOIs", "uncontrolled narrow-angle glaucoma", "severe hepatic impairment"],
      "black_box_warnings": ["Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults"],
      "pregnancy_category": "C",
      "half_life": "12 hours",
      "metabolism": "Hepatic (CYP1A2, CYP2D6)",
      "excretion": "Urine (70%), feces (20%)",
      "monitoring_parameters": ["Mental status for depression, anxiety, suicidal ideation", "Liver function tests", "Blood pressure", "Emerging side effects"],
      "drug_interactions": ["MAOIs", "Other serotonergic drugs", "CYP1A2 inhibitors", "CYP2D6 inhibitors", "Warfarin", "NSAIDs", "Triptans"],
      "patient_instructions": ["Swallow whole - do not crush, chew, or open capsule", "Take with or without food", "Do not stop abruptly", "Report worsening depression, suicidal thoughts, unusual behavior changes", "May take several weeks to achieve full therapeutic effect"]
    },
    {
      "name": "Pantoprazole",
      "generic_name": "pantoprazole sodium",
      "brand_names": ["Protonix", "Pantoloc", "Pantozol", "Panto IV", "Zurcal"],
      "drug_class": "Proton pump inhibitor",
      "indication": "GERD, erosive esophagitis, pathological hypersecretory conditions including Zollinger-Ellison syndrome, H. pylori eradication (in combination)",
      "mechanism": "Irreversibly binds to H+/K+-ATPase enzyme system at secretory surface of gastric parietal cells, inhibiting the final step of acid production.",
      "dosage_forms": ["delayed-release tablet", "delayed-release oral suspension", "injection"],
      "common_dosages": ["20mg", "40mg"],
      "side_effects": ["headache", "diarrhea", "nausea", "abdominal pain", "flatulence", "dizziness", "arthralgia", "C. difficile infection", "bone fractures", "hypomagnesemia"],
      "contraindications": ["hypersensitivity to pantoprazole or substituted benzimidazoles"],
      "black_box_warnings": ["None"],
      "pregnancy_category": "B",
      "half_life": "1 hour",
      "metabolism": "Hepatic (CYP2C19, CYP3A4)",
      "excretion": "Urine (71%), feces (18%)",
      "monitoring_parameters": ["Symptoms of GERD", "Magnesium levels with prolonged use", "Bone density with long-term use"],
      "drug_interactions": ["Drugs requiring gastric acid for absorption (e.g., ketoconazole, iron salts)", "Warfarin", "Methotrexate", "Clopidogrel", "Atazanavir"],
      "patient_instructions": ["Take before meals", "Swallow tablet whole - do not crush or chew", "Report persistent diarrhea, bone pain, muscle spasms", "Consider calcium and vitamin D supplementation with long-term use"]
    },
    {
      "name": "Tramadol",
      "generic_name": "tramadol hydrochloride",
      "brand_names": ["Ultram", "ConZip", "Ryzolt", "Ultram ER", "Dolol", "Tridol"],
      "drug_class": "Opioid agonist, serotonin/norepinephrine reuptake inhibitor",
      "indication": "Moderate to moderately severe pain",
      "mechanism": "Binds to mu-opioid receptors and weakly inhibits reuptake of serotonin and norepinephrine. The O-desmethyl metabolite has higher affinity for mu-opioid receptors.",
      "dosage_forms": ["tablet", "extended-release tablet", "capsule", "oral solution"],
      "common_dosages": ["50mg", "100mg", "150mg", "200mg", "300mg ER", "100mg ER", "200mg ER", "300mg ER"],
      "side_effects": ["nausea", "dizziness", "constipation", "headache", "somnolence", "vomiting", "pruritus", "CNS depression", "seizures", "serotonin syndrome"],
      "contraindications": ["significant respiratory depression", "acute or severe bronchial asthma", "GI obstruction", "concomitant use with MAOIs or serotonin precursors", "suicide risk"],
      "black_box_warnings": ["Addiction, abuse, and misuse risk", "Life-threatening respiratory depression", "Accidental ingestion risk", "Neonatal opioid withdrawal syndrome", "CYP2D6 ultra-rapid metabolizers risk", "Serotonin syndrome risk", "Increased seizure risk"],
      "pregnancy_category": "C",
      "half_life": "6-7 hours (parent), 7-9 hours (active metabolite)",
      "metabolism": "Hepatic (CYP2D6, CYP3A4)",
      "excretion": "Urine (30% unchanged, 60% as metabolites)",
      "monitoring_parameters": ["Pain control", "Respiratory depression", "Signs of misuse/abuse", "Bowel function", "Seizure activity", "Serotonin syndrome symptoms"],
      "drug_interactions": ["CNS depressants", "MAOIs", "Serotonergic drugs", "CYP2D6 inhibitors", "CYP3A4 inhibitors", "Quinidine", "Carbamazepine"],
      "patient_instructions": ["Take as needed for pain", "Do not crush or chew extended-release formulations", "Avoid alcohol", "Report difficulty breathing, excessive drowsiness", "May cause dependence with long-term use", "Do not stop abruptly after long-term use"]
    },
    {
      "name": "Venlafaxine",
      "generic_name": "venlafaxine hydrochloride",
      "brand_names": ["Effexor", "Effexor XR", "Venlor", "Trevilor", "Vencarm", "Vandral"],
      "drug_class": "Serotonin-norepinephrine reuptake inhibitor (SNRI)",
      "indication": "Major depressive disorder, generalized anxiety disorder, social anxiety disorder, panic disorder",
      "mechanism": "Inhibits serotonin and norepinephrine reuptake, and weakly inhibits dopamine reuptake. The O-desmethyl metabolite is also pharmacologically active.",
      "dosage_forms": ["tablet", "extended-release capsule", "extended-release tablet"],
      "common_dosages": ["25mg", "37.5mg", "50mg", "75mg", "100mg", "150mg", "225mg XR", "37.5mg XR", "75mg XR", "150mg XR"],
      "side_effects": ["nausea", "headache", "insomnia", "dry mouth", "dizziness", "somnolence", "increased sweating", "nervousness", "hypertension", "sexual dysfunction", "appetite decrease"],
      "contraindications": ["concomitant use with MAOIs", "hypersensitivity to venlafaxine"],
      "black_box_warnings": ["Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults"],
      "pregnancy_category": "C",
      "half_life": "5 hours (parent), 11 hours (active metabolite)",
      "metabolism": "Hepatic (CYP2D6)",
      "excretion": "Urine (87%)",
      "monitoring_parameters": ["Blood pressure", "Mental status for depression, anxiety, suicidal ideation", "Emerging side effects"],
      "drug_interactions": ["MAOIs", "Serotonergic drugs", "CYP2D6 inhibitors", "Warfarin", "Triptans", "Linezolid", "Methylene blue"],
      "patient_instructions": ["Take with food", "Swallow extended-release capsules whole", "Do not stop abruptly", "Report worsening depression, suicidal thoughts, unusual behavior changes", "May take several weeks to achieve full therapeutic effect", "Monitor blood pressure regularly"]
    },
    {
      "name": "Fluoxetine",
      "generic_name": "fluoxetine hydrochloride",
      "brand_names": ["Prozac", "Sarafem", "Selfemra", "Fontex", "Fluctin", "Ladose", "Prozep"],
      "drug_class": "Selective serotonin reuptake inhibitor (SSRI)",
      "indication": "Major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, premenstrual dysphoric disorder",
      "mechanism": "Selectively inhibits serotonin reuptake in the presynaptic neuron, increasing synaptic concentration of serotonin. Has a long half-life due to active metabolite norfluoxetine.",
      "dosage_forms": ["capsule", "tablet", "delayed-release capsule", "oral solution", "weekly capsule"],
      "common_dosages": ["10mg", "20mg", "40mg", "60mg", "80mg", "90mg weekly"],
      "side_effects": ["insomnia", "nausea", "headache", "anxiety", "nervousness", "drowsiness", "fatigue", "diarrhea", "decreased libido", "sweating", "rash"],
      "contraindications": ["concomitant use with MAOIs or thioridazine", "pimozide", "disulfiram (for oral solution)"],
      "black_box_warnings": ["Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults"],
      "pregnancy_category": "C",
      "half_life": "4-6 days (after chronic administration), 4-16 days for norfluoxetine",
      "metabolism": "Hepatic (CYP2D6) to active metabolite norfluoxetine",
      "excretion": "Urine (60%), feces (15%)",
      "monitoring_parameters": ["Mental status for depression, anxiety, suicidal ideation", "Emerging side effects"],
      "drug_interactions": ["MAOIs", "Tricyclic antidepressants", "Phenytoin", "Warfarin", "Tryptophan", "Lithium", "Tramadol", "Linezolid", "Thioridazine", "Pimozide"],
      "patient_instructions": ["Take in morning to minimize insomnia", "May take with food to reduce GI upset", "Do not stop abruptly", "Report worsening depression, suicidal thoughts, unusual behavior changes", "Allow several weeks for full therapeutic effect", "Avoid alcohol"]
    },
    {
      "name": "Furosemide",
      "generic_name": "furosemide",
      "brand_names": ["Lasix", "Fruse", "Furosix", "Furosedon", "Seguril", "Diurapid"],
      "drug_class": "Loop diuretic",
      "indication": "Edema associated with heart failure, hepatic cirrhosis, renal disease, hypertension",
      "mechanism": "Inhibits sodium and chloride reabsorption in the ascending loop of Henle and distal renal tubule, increasing excretion of water, sodium, chloride, magnesium, calcium, and potassium.",
      "dosage_forms": ["tablet", "oral solution", "injection"],
      "common_dosages": ["20mg", "40mg", "80mg", "500mg IV", "10mg/mL oral solution"],
      "side_effects": ["dehydration", "hypotension", "hypokalemia", "hyponatremia", "hypochloremia", "hypocalcemia", "hypomagnesemia", "ototoxicity", "hyperglycemia", "hyperuricemia"],
      "contraindications": ["anuria", "hepatic coma", "electrolyte depletion", "hypersensitivity to sulfonamides"],
      "black_box_warnings": ["None"],
      "pregnancy_category": "C",
      "half_life": "0.5-2 hours",
      "metabolism": "Hepatic (minimal)",
      "excretion": "Renal (66%), fecal (33%)",
      "monitoring_parameters": ["Blood pressure", "Fluid balance", "Electrolytes", "Renal function", "Hearing (with high doses)"],
      "drug_interactions": ["Aminoglycosides", "Digoxin", "Lithium", "NSAIDs", "Probenecid", "Sucralfate", "Cisplatin", "ACE inhibitors"],
      "patient_instructions": ["Take in morning to avoid nocturia", "Take with food to reduce GI upset", "Report signs of electrolyte imbalance (muscle cramps, weakness, dizziness)", "Weigh daily", "Rise slowly from sitting/lying position", "Avoid excessive sun exposure"]
    },
    {
      "name": "Montelukast",
      "generic_name": "montelukast sodium",
      "brand_names": ["Singulair", "Montek", "Montair", "Lukast", "Monteka", "Azmiral"],
      "drug_class": "Leukotriene receptor antagonist",
      "indication": "Asthma prophylaxis and chronic treatment, exercise-induced bronchoconstriction, allergic rhinitis",
      "mechanism": "Selectively blocks leukotriene D4 (LTD4) at cysteinyl leukotriene receptors, inhibiting airway edema, smooth muscle contraction, and inflammatory cell activity.",
      "dosage_forms": ["tablet", "chewable tablet", "oral granules"],
      "common_dosages": ["4mg", "5mg", "10mg"],
      "side_effects": ["headache", "dizziness", "fatigue", "abdominal pain", "heartburn", "cough", "fever", "upper respiratory infection", "neuropsychiatric events"],
      "contraindications": ["hypersensitivity to montelukast"],
      "black_box_warnings": ["Serious neuropsychiatric events"],
      "pregnancy_category": "B",
      "half_life": "2.7-5.5 hours",
      "metabolism": "Hepatic (CYP3A4, CYP2C9)",
      "excretion": "Feces (86%)",
      "monitoring_parameters": ["Asthma symptoms", "Asthma control", "Neuropsychiatric symptoms", "ALT/AST (if clinical indication)"],
      "drug_interactions": ["Phenobarbital", "Rifampin", "Gemfibrozil", "Cyclosporine", "Efavirenz"],
      "patient_instructions": ["Take once daily in evening", "Not for acute asthma attacks", "Report behavior or mood changes, agitation, depression, suicidal thoughts", "Continue other asthma medications unless directed otherwise", "May take with or without food"]
    },
    {
      "name": "Quetiapine",
      "generic_name": "quetiapine fumarate",
      "brand_names": ["Seroquel", "Seroquel XR", "Ketipinor", "Quentin", "Qutan", "Quepin", "Biquelle"],
      "drug_class": "Atypical antipsychotic",
      "indication": "Schizophrenia, bipolar disorder, major depressive disorder (adjunct)",
      "mechanism": "Antagonizes dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptors. Also has antagonist activity at histamine H1, adrenergic Î±1, and serotonin 5-HT1A receptors.",
      "dosage_forms": ["tablet", "extended-release tablet"],
      "common_dosages": ["25mg", "50mg", "100mg", "200mg", "300mg", "400mg", "150mg XR", "200mg XR", "300mg XR", "400mg XR"],
      "side_effects": ["somnolence", "dizziness", "dry mouth", "constipation", "weight gain", "dyslipidemia", "hyperglycemia", "orthostatic hypotension", "cataracts", "extrapyramidal symptoms"],
      "contraindications": ["hypersensitivity to quetiapine"],
      "black_box_warnings": ["Increased mortality in elderly patients with dementia-related psychosis", "Suicidal thoughts and behaviors in children, adolescents, and young adults"],
      "pregnancy_category": "C",
      "half_life": "6 hours (immediate-release), 7 hours (extended-release)",
      "metabolism": "Hepatic (CYP3A4)",
      "excretion": "Urine (73%), feces (20%)",
      "monitoring_parameters": ["Mental status", "Weight", "Fasting blood glucose", "Lipid profile", "Cataract screening", "Extrapyramidal symptoms"],
      "drug_interactions": ["CYP3A4 inhibitors/inducers", "Antihypertensives", "CNS depressants", "Dopamine agonists", "Levodopa", "Alcohol"],
      "patient_instructions": ["Take without food or with light meal", "Swallow extended-release tablets whole", "Avoid alcohol", "Rise slowly from sitting/lying position", "Report vision changes, involuntary movements", "Do not stop abruptly"]
    },
    {
      "name": "Rosuvastatin",
      "generic_name": "rosuvastatin calcium",
      "brand_names": ["Crestor", "Rovasta", "Vytorin", "Rosuvas", "Vytorin", "Tresor"],
      "drug_class": "HMG-CoA reductase inhibitor (statin)",
      "indication": "Hyperlipidemia, primary prevention of cardiovascular disease, slowing atherosclerosis progression",
      "mechanism": "Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Increases hepatic LDL receptors, enhancing clearance of LDL from bloodstream.",
      "dosage_forms": ["tablet"],
      "common_dosages": ["5mg", "10mg", "20mg", "40mg"],
      "side_effects": ["headache", "myalgia", "abdominal pain", "nausea", "constipation", "dizziness", "asthenia", "rhabdomyolysis", "liver enzyme elevation", "proteinuria"],
      "contraindications": ["active liver disease", "pregnancy", "breastfeeding", "unexplained persistent elevations of serum transaminases"],
      "black_box_warnings": ["Rhabdomyolysis risk", "Liver enzyme abnormalities"],
      "pregnancy_category": "X",
      "half_life": "19 hours",
      "metabolism": "Limited hepatic (CYP2C9, CYP2C19)",
      "excretion": "Feces (90%), urine (10%)",
      "monitoring_parameters": ["Lipid panel", "LFTs", "CPK if symptomatic"],
      "drug_interactions": ["Cyclosporine", "Gemfibrozil", "Protease inhibitors", "Warfarin", "Niacin", "Colchicine", "Antacids"],
      "patient_instructions": ["Take with or without food", "Report unexplained muscle pain/tenderness/weakness", "Avoid excessive alcohol consumption", "Follow cholesterol-lowering diet", "Regular exercise program"]
    },
    {
      "name": "Tamsulosin",
      "generic_name": "tamsulosin hydrochloride",
      "brand_names": ["Flomax", "Urimax", "Prolosin", "Tamsin", "Contiflo", "Tamfulo"],
      "drug_class": "Selective alpha-1 adrenergic blocker",
      "indication": "Benign prostatic hyperplasia (BPH)",
      "mechanism": "Selectively blocks alpha-1A adrenergic receptors in the prostate and bladder neck, relaxing smooth muscle and improving urine flow and BPH symptoms.",
      "dosage_forms": ["capsule", "modified-release tablet"],
      "common_dosages": ["0.4mg", "0.2mg", "0.8mg"],
      "side_effects": ["dizziness", "abnormal ejaculation", "headache", "orthostatic hypotension", "rhinitis", "somnolence", "decreased libido", "intraoperative floppy iris syndrome"],
      "contraindications": ["hypersensitivity to tamsulosin", "history of orthostatic hypotension"],
      "black_box_warnings": ["None"],
      "pregnancy_category": "B (not indicated in women)",
      "half_life": "9-13 hours",
      "metabolism": "Hepatic (CYP3A4, CYP2D6)",
      "excretion": "Urine (76%), feces (21%)",
      "monitoring_parameters": ["BPH symptoms", "Blood pressure", "Orthostatic symptoms", "PSA (if clinically indicated)"],
      "drug_interactions": ["Other alpha-blockers", "Phosphodiesterase-5 inhibitors", "CYP3A4 inhibitors", "CYP2D6 inhibitors", "Warfarin"],
      "patient_instructions": ["Take 30 minutes after same meal each day", "Do not crush, chew, or open capsules", "Rise slowly from sitting/lying position", "Report dizziness, fainting", "Inform ophthalmologist about tamsulosin use before cataract surgery"]
    },
    {
      "name": "Clopidogrel",
      "generic_name": "clopidogrel bisulfate",
      "brand_names": ["Plavix", "Clopilet", "Ceruvin", "Clopidogrel", "Plagril", "Zylagren"],
      "drug_class": "P2Y12 platelet ADP receptor inhibitor",
      "indication": "Acute coronary syndrome, recent MI, recent stroke, peripheral arterial disease",
      "mechanism": "Selectively inhibits ADP binding to P2Y12 receptor on platelets, preventing ADP-mediated activation of GPIIb/IIIa complex and platelet aggregation.",
      "dosage_forms": ["tablet"],
      "common_dosages": ["75mg", "300mg loading dose"],
      "side_effects": ["bleeding", "bruising", "rash", "diarrhea", "abdominal pain", "dyspepsia", "thrombotic thrombocytopenic purpura", "neutropenia"],
      "contraindications": ["active pathological bleeding", "severe liver impairment", "hypersensitivity to clopidogrel"],
      "black_box_warnings": ["Diminished effectiveness in CYP2C19 poor metabolizers"],
      "pregnancy_category": "B",
      "half_life": "6 hours (parent), 30 minutes (active metabolite)",
      "metabolism": "Hepatic (CYP2C19, CYP3A4, CYP2B6, CYP1A2) to active metabolite",
      "excretion": "Urine (50%), feces (46%)",
      "monitoring_parameters": ["Signs of bleeding", "CBC", "Thrombotic events"],
      "drug_interactions": ["Other antiplatelets/anticoagulants", "NSAIDs", "Proton pump inhibitors (especially omeprazole)", "CYP2C19 inhibitors", "Fluconazole", "Efavirenz"],
      "patient_instructions": ["Take with or without food", "Do not stop without consulting doctor", "Report unusual bleeding/bruising", "Inform dentists/doctors about clopidogrel use before procedures", "Avoid activities with high risk of bleeding"]
    },
    {
      "name": "Bupropion",
      "generic_name": "bupropion hydrochloride",
      "brand_names": ["Wellbutrin", "Wellbutrin SR", "Wellbutrin XL", "Zyban", "Aplenzin", "Forfivo XL"],
      "drug_class": "Aminoketone antidepressant",
      "indication": "Major depressive disorder, seasonal affective disorder, smoking cessation",
      "mechanism": "Weakly inhibits norepinephrine and dopamine reuptake. Does not inhibit MAO or serotonin reuptake. Mechanism for smoking cessation is unknown.",
      "dosage_forms": ["tablet", "extended-release tablet", "sustained-release tablet"],
      "common_dosages": ["75mg", "100mg", "150mg", "200mg SR", "300mg SR", "150mg XL", "300mg XL", "450mg XL"],
      "side_effects": ["insomnia", "headache", "dry mouth", "nausea", "constipation", "anxiety", "tremor", "increased sweating", "tinnitus", "seizures"],
      "contraindications": ["seizure disorder", "current/prior diagnosis of bulimia or anorexia nervosa", "concomitant MAOI use", "abrupt discontinuation of alcohol/sedatives"],
      "black_box_warnings": ["Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults"],
      "pregnancy_category": "C",
      "half_life": "21 hours (parent), 20-27 hours (metabolites)",
      "metabolism": "Hepatic (CYP2B6)",
      "excretion": "Urine (87%), feces (10%)",
      "monitoring_parameters": ["Mental status for depression, suicidal ideation", "Blood pressure", "Seizure activity"],
      "drug_interactions": ["MAOIs", "Other antidepressants", "Antipsychotics", "Theophylline", "Corticosteroids", "CYP2B6 inhibitors", "Alcohol", "Levodopa"],
      "patient_instructions": ["Take with or without food", "Do not crush or chew extended-release tablets", "Avoid alcohol", "Report mood changes, suicidal thoughts", "May cause insomnia - take morning dose early", "Do not stop abruptly"]
    },
    {
      "name": "Diazepam",
      "generic_name": "diazepam",
      "brand_names": ["Valium", "Diazemuls", "Stesolid", "Vival", "Apaurin", "Valaxona"],
      "drug_class": "Benzodiazepine",
      "indication": "Anxiety disorders, alcohol withdrawal, skeletal muscle spasm, seizure disorders, preoperative sedation",
      "mechanism": "Enhances GABA effects by binding to benzodiazepine receptors on GABA-A receptor complex, increasing neuronal membrane permeability to chloride ions resulting in hyperpolarization and reduced neuronal excitability.",
      "dosage_forms": ["tablet", "oral solution", "injection", "rectal gel"],
      "common_dosages": ["2mg", "5mg", "10mg", "5mg/5mL oral solution", "5mg/mL injection"],
      "side_effects": ["drowsiness", "fatigue", "ataxia", "confusion", "hypotension", "respiratory depression", "dependence", "withdrawal symptoms", "paradoxical reactions"],
      "contraindications": ["narrow-angle glaucoma", "severe respiratory insufficiency", "severe hepatic impairment", "sleep apnea", "myasthenia gravis"],
      "black_box_warnings": ["Concomitant use with opioids", "Abuse, misuse, and addiction risk"],
      "pregnancy_category": "D",
      "half_life": "20-50 hours (parent), 50-100 hours (active metabolites)",
      "metabolism": "Hepatic (CYP2C19, CYP3A4) to active metabolites",
      "excretion": "Urine (mainly as metabolites)",
      "monitoring_parameters": ["Respiratory status", "Mental status", "Signs of misuse/dependence", "Liver function"],
      "drug_interactions": ["CNS depressants", "Opioids", "Alcohol", "CYP3A4 inhibitors", "CYP2C19 inhibitors", "Probenecid", "Disulfiram"],
      "patient_instructions": ["Avoid alcohol", "Do not drive or operate machinery", "Do not stop abruptly", "Report excessive drowsiness, confusion", "Take exactly as prescribed", "Store securely to prevent misuse"]
    },
    {
      "name": "Esomeprazole",
      "generic_name": "esomeprazole magnesium",
      "brand_names": ["Nexium", "Esomezol", "Nexium IV", "Esopral", "Emanera", "Sompraz"],
      "drug_class": "Proton pump inhibitor",
      "indication": "GERD, erosive esophagitis, H. pylori eradication, pathological hypersecretory conditions, NSAID-induced ulcer risk reduction",
      "mechanism": "The S-isomer of omeprazole. Irreversibly binds to H+/K+-ATPase enzyme system at secretory surface of gastric parietal cells, inhibiting the final step of acid production.",
      "dosage_forms": ["delayed-release capsule", "delayed-release tablet", "injection", "oral suspension"],
      "common_dosages": ["20mg", "40mg"],
      "side_effects": ["headache", "diarrhea", "nausea", "abdominal pain", "flatulence", "constipation", "dry mouth", "C. difficile infection", "bone fractures", "hypomagnesemia"],
      "contraindications": ["hypersensitivity to esomeprazole or substituted benzimidazoles"],
      "black_box_warnings": ["None"],
      "pregnancy_category": "B",
      "half_life": "1-1.5 hours",
      "metabolism": "Hepatic (CYP2C19, CYP3A4)",
      "excretion": "Urine (80%), feces (20%)",
      "monitoring_parameters": ["Symptoms of GERD", "Magnesium levels with prolonged use", "Bone density with long-term use"],
      "drug_interactions": ["Drugs requiring gastric acid for absorption", "Clopidogrel", "CYP2C19 substrates", "Methotrexate", "Tacrolimus", "Diazepam", "Warfarin"],
      "patient_instructions": ["Take at least 1 hour before meals", "Swallow capsules whole", "Do not crush or chew", "Report persistent diarrhea, bone pain, muscle spasms", "Consider calcium and vitamin D supplementation with long-term use"]
    },
    {
      "name": "Glipizide",
      "generic_name": "glipizide",
      "brand_names": ["Glucotrol", "Glucotrol XL", "Glibenese", "Minodiab", "Melizide", "Glucopyride"],
      "drug_class": "Sulfonylurea",
      "indication": "Type 2 diabetes mellitus",
      "mechanism": "Stimulates insulin release from pancreatic beta cells, reduces glucose output from liver, increases insulin sensitivity at peripheral target sites.",
      "dosage_forms": ["tablet", "extended-release tablet"],
      "common_dosages": ["5mg", "10mg", "2.5mg", "5mg XL", "10mg XL"],
      "side_effects": ["hypoglycemia", "nausea", "dizziness", "headache", "weight gain", "skin reactions", "GI disturbances", "hematologic reactions"],
      "contraindications": ["Type 1 diabetes", "diabetic ketoacidosis", "hypersensitivity to sulfonylureas", "concomitant use with bosentan"],
      "black_box_warnings": ["Increased cardiovascular mortality"],
      "pregnancy_category": "C",
      "half_life": "2-4 hours",
      "metabolism": "Hepatic (CYP2C9) to inactive metabolites",
      "excretion": "Urine (80%), feces (10%)",
      "monitoring_parameters": ["Blood glucose", "HbA1c", "Hypoglycemia symptoms", "Liver function", "Renal function"],
      "drug_interactions": ["Beta-blockers", "Alcohol", "Warfarin", "MAOIs", "NSAIDs", "Sulfonamides", "Fluconazole", "Bosentan"],
      "patient_instructions": ["Take 30 minutes before meals", "Do not crush or chew extended-release tablets", "Recognize and treat hypoglycemia", "Eat consistent meals", "Avoid alcohol", "Carry glucose source"]
    },
    {
      "name": "Ibuprofen",
      "generic_name": "ibuprofen",
      "brand_names": ["Advil", "Motrin", "Nurofen", "Brufen", "Ibuprom", "Ibugesic", "Ibumetin"],
      "drug_class": "Nonsteroidal anti-inflammatory drug (NSAID)",
      "indication": "Mild to moderate pain, inflammation, fever, dysmenorrhea, rheumatoid arthritis, osteoarthritis",
      "mechanism": "Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.",
      "dosage_forms": ["tablet", "capsule", "oral suspension", "chewable tablet", "topical gel", "injection"],
      "common_dosages": ["200mg", "400mg", "600mg", "800mg", "100mg/5mL suspension"],
      "side_effects": ["GI upset", "dyspepsia", "heartburn", "nausea", "GI ulceration/bleeding", "headache", "dizziness", "renal impairment", "hypertension", "elevated LFTs"],
      "contraindications": ["perioperative coronary artery bypass graft pain", "active peptic ulcer disease", "GI bleeding", "severe renal impairment", "third trimester pregnancy", "hypersensitivity to NSAIDs"],
      "black_box_warnings": ["Increased risk of serious cardiovascular thrombotic events", "Increased risk of serious GI adverse events"],
      "pregnancy_category": "C (first and second trimester), D (third trimester)",
      "half_life": "2-4 hours",
      "metabolism": "Hepatic (CYP2C9)",
      "excretion": "Urine (90%)",
      "monitoring_parameters": ["Renal function", "Liver function", "Hemoglobin", "Blood pressure", "GI symptoms"],
      "drug_interactions": ["Aspirin", "Other NSAIDs", "Anticoagulants", "ACE inhibitors", "Diuretics", "Lithium", "Methotrexate", "Cyclosporine"],
      "patient_instructions": ["Take with food or milk to reduce GI upset", "Do not exceed recommended dosage", "Report signs of GI bleeding (black stools, abdominal pain)", "Avoid alcohol", "Use lowest effective dose for shortest duration"]
    },
    {
      "name": "Lorazepam",
      "generic_name": "lorazepam",
      "brand_names": ["Ativan", "Temesta", "Lorabenz", "Apo-Lorazepam", "Lorazep", "Lorax"],
      "drug_class": "Benzodiazepine",
      "indication": "Anxiety disorders, anxiety-associated insomnia, status epilepticus, preoperative sedation, chemotherapy-induced nausea/vomiting",
      "mechanism": "Enhances GABA effects by binding to benzodiazepine receptors on GABA-A receptor complex, increasing neuronal membrane permeability to chloride ions resulting in hyperpolarization and reduced neuronal excitability.",
      "dosage_forms": ["tablet", "oral concentrate", "injection", "oral solution"],
      "common_dosages": ["0.5mg", "1mg", "2mg", "2mg/mL injection", "2mg/mL oral solution"],
      "side_effects": ["sedation", "dizziness", "weakness", "unsteadiness", "respiratory depression", "dependence", "withdrawal symptoms", "paradoxical reactions", "amnesia"],
      "contraindications": ["narrow-angle glaucoma", "severe respiratory insufficiency", "sleep apnea", "myasthenia gravis", "severe hepatic impairment"],
      "black_box_warnings": ["Concomitant use with opioids", "Abuse, misuse, and addiction risk"],
      "pregnancy_category": "D",
      "half_life": "12-18 hours",
      "metabolism": "Hepatic glucuronidation (no CYP450 involvement)",
      "excretion": "Urine (88%), feces (7%)",
      "monitoring_parameters": ["Respiratory status", "Mental status", "Signs of misuse/dependence", "Liver function"],
      "drug_interactions": ["CNS depressants", "Opioids", "Alcohol", "Probenecid", "Valproic acid", "Oral contraceptives"],
      "patient_instructions": ["Avoid alcohol", "Do not drive or operate machinery", "Do not stop abruptly", "Report excessive drowsiness, confusion", "Take exactly as prescribed", "Store securely to prevent misuse"]
    },
    {
      "name": "Meloxicam",
      "generic_name": "meloxicam",
      "brand_names": ["Mobic", "Movalis", "Melox", "Rheumocam", "Mobicox", "Revicam"],
      "drug_class": "Nonsteroidal anti-inflammatory drug (NSAID)",
      "indication": "Osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis",
      "mechanism": "Inhibits cyclooxygenase (COX-2 greater than COX-1), reducing prostaglandin synthesis, which mediates pain and inflammation.",
      "dosage_forms": ["tablet", "oral suspension", "injection"],
      "common_dosages": ["7.5mg", "15mg"],
      "side_effects": ["GI upset", "dyspepsia", "nausea", "abdominal pain", "diarrhea", "headache", "dizziness", "edema", "hypertension", "elevated LFTs", "GI ulceration/bleeding"],
      "contraindications": ["perioperative coronary artery bypass graft pain", "active peptic ulcer disease", "GI bleeding", "severe renal impairment", "third trimester pregnancy", "hypersensitivity to NSAIDs"],
      "black_box_warnings": ["Increased risk of serious cardiovascular thrombotic events", "Increased risk of serious GI adverse events"],
      "pregnancy_category": "C (first and second trimester), D (third trimester)",
      "half_life": "15-20 hours",
      "metabolism": "Hepatic (CYP2C9, CYP3A4)",
      "excretion": "Urine and feces",
      "monitoring_parameters": ["Renal function", "Liver function", "Hemoglobin", "Blood pressure", "GI symptoms"],
      "drug_interactions": ["Aspirin", "Other NSAIDs", "Anticoagulants", "ACE inhibitors", "Diuretics", "Lithium", "Methotrexate"],
      "patient_instructions": ["Take with food or milk to reduce GI upset", "Do not exceed recommended dosage", "Report signs of GI bleeding (black stools, abdominal pain)", "Avoid alcohol", "Use lowest effective dose for shortest duration"]
    }
    ]
}